Summit Therapeutics SMMT Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's common stock, par value (in dollars per share)?
- Summit Therapeutics (SMMT) reported common stock, par value (in dollars per share) of $0.01 in Q1 2026.
- How has Summit Therapeutics's common stock, par value (in dollars per share) changed year-over-year?
- Summit Therapeutics's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0.01 to $0.01.
- What is the long-term trend for Summit Therapeutics's common stock, par value (in dollars per share)?
- Over 5 years (2020 to 2025), Summit Therapeutics's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.